Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2023-08-29 Board/Management Inform…
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Scancell Appoints Sath Nirmalananthan as CFO
Board/Management Information Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number : 5469K) on August 29, 2023. The content explicitly announces the appointment of a new Chief Financial Officer (Sath Nirmalananthan) and the retirement of the previous Director of Finance (Keith Green). This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. Although it is distributed via RNS, the specific content is management change, making MANG the most precise classification over the general RNS fallback.
2023-08-29 English
Modi-1 trial open for expansion in CPI combination
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated July 31, 2023. It contains standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content itself is an announcement regarding clinical trial updates (Modi-1 trial expansion) for Scancell Holdings Plc, which is typical for a regulatory news service release. Since it is a general regulatory announcement that doesn't fit the specific categories like ER, 10-K, or DIV, the most appropriate classification is the general regulatory filing category.
2023-07-31 English
Extension of exercise period for CEO share options
Remuneration Information Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date stamp typical of regulatory news services. The content announces an extension of share option exercise periods for the CEO, which involves a related party transaction under AIM Rules. This type of announcement, which is a formal notification to the market via the London Stock Exchange's RNS system, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a director's dealing (DIRS), but rather a specific corporate action disclosure disseminated through the regulatory channel. Given the structure and the explicit mention of RNS and the London Stock Exchange, RNS (Regulatory Filings) is the most appropriate classification, as it serves as the general regulatory announcement fallback.
2023-07-13 English
Pipeline strategy and business update
Regulatory Filings Classification · 98% confidence The document is a formal announcement from Scancell Holdings Plc, dated July 10, 2023, providing an update on its pipeline strategy, clinical trials (SCOPE and ModiFY), and financial runway. It contains key operational and clinical highlights, quotes from the CEO, and details about ongoing studies. This structure—providing key results and strategic direction outside of a full annual or quarterly filing—is characteristic of an Earnings Release (ER) or a general business update. Since it focuses on recent operational progress and financial standing (cash runway), it aligns best with the 'Earnings Release' definition, which covers initial announcements of periodical financial results and key highlights. It is not a full 10-K, an Interim Report (IR), or a transcript (CT). Given the content focuses on recent performance updates and outlook, ER is the most appropriate classification.
2023-07-10 English
Scancell to Present Modi-1 Data at ASCO
Legal Proceedings Report Classification · 99% confidence The document is identified by the RNS Number header and the closing statement referencing RNS, the news service of the London Stock Exchange, which suggests it is a regulatory announcement. The content details the company's plan to present clinical trial protocol and early efficacy data at the American Society of Clinical Oncology (ASCO) Meeting. This is an announcement about presenting scientific/investor-related information, not the full financial report (10-K, IR) or a formal earnings release (ER). Since it is a specific announcement disseminated via the RNS system that doesn't fit perfectly into the other specific categories (like DIV, DIRS, MANG), the most appropriate classification is the general regulatory announcement category, RNS, as it is a formal regulatory news service release.
2023-06-02 English
Issue of share options to Non-Executive Directors
Director's Dealing Classification · 100% confidence The document is an official announcement disseminated via RNS (RNS Number : 9791W) dated April 21, 2023. The content explicitly details the 'Issue of share options to Non-Executive Directors' and includes a mandatory 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM' section, which is typical for insider transactions or grants involving directors. This falls under the category of reporting personal share transactions by company directors and executives. Therefore, the most appropriate classification is Director's Dealing (DIRS). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a general capital change (SHA) as it specifically concerns director compensation/insider activity.
2023-04-21 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.